Renaissance Technologies LLC Purchases 108,185 Shares of Embecta Corp. $EMBC

Renaissance Technologies LLC increased its position in shares of Embecta Corp. (NASDAQ:EMBC) by 299.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 144,287 shares of the company’s stock after purchasing an additional 108,185 shares during the period. Renaissance Technologies LLC owned approximately 0.24% of Embecta worth $1,275,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its stake in Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after buying an additional 6,224 shares during the last quarter. Wexford Capital LP bought a new position in shares of Embecta during the third quarter valued at approximately $94,000. Humankind Investments LLC purchased a new stake in shares of Embecta in the second quarter worth approximately $111,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Embecta in the third quarter worth approximately $115,000. 93.83% of the stock is currently owned by institutional investors.

More Embecta News

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: CEO Devdatt Kurdikar purchased 30,000 shares for approximately $141,000, while CFO Jacob Elguicze bought 20,000 shares for about $93,400. Director Jeffrey Z. Mann also acquired 20,000 shares for roughly $99,800. The coordinated purchases—made near recent lows and disclosed in SEC filings—may signal that senior leaders view the stock as undervalued or believe the company’s long-term outlook is stronger than its recent performance suggests. Embecta CEO insider purchase filing
• Neutral Sentiment: Multiple law firms publicized the same pending securities class action and the August 17 lead-plaintiff deadline for investors who purchased Embecta shares between November 25, 2025, and May 4, 2026. The announcements largely seek participation and do not represent new findings or a court judgment against Embecta. Rosen Embecta class action deadline notice
• Negative Sentiment: The litigation alleges that Embecta misrepresented the commercial stability of its insulin pen-needle business and that its CEO and CFO issued misleading fiscal 2026 guidance. Plaintiffs claim the disclosures contributed to a sharp stock decline, potentially exposing Embecta and certain executives to financial liability, legal expenses, and reputational damage. These are allegations, and their ultimate merits remain unresolved. Hagens Berman Embecta lawsuit investigation

Embecta Stock Up 7.6%

Shares of NASDAQ:EMBC opened at $5.11 on Friday. Embecta Corp. has a 52-week low of $2.77 and a 52-week high of $15.55. The stock has a market cap of $289.53 million, a P/E ratio of 3.45 and a beta of 0.81. The business’s 50 day moving average is $3.46 and its 200 day moving average is $6.42.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Friday, August 7th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.27 by $0.29. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The company had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. During the same period last year, the business posted $1.12 EPS. Embecta’s quarterly revenue was down 8.1% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, sell-side analysts anticipate that Embecta Corp. will post 1.84 EPS for the current fiscal year.

Embecta Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Thursday, August 27th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Thursday, August 27th. Embecta’s payout ratio is presently 2.70%.

Analysts Set New Price Targets

EMBC has been the subject of a number of recent analyst reports. Weiss Ratings cut Embecta from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Mizuho reduced their target price on Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Bank of America lowered their target price on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research note on Monday, May 18th. Finally, Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $11.00.

Insider Activity at Embecta

In other Embecta news, CEO Devdatt Kurdikar bought 30,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were acquired at an average price of $4.70 per share, with a total value of $141,000.00. Following the transaction, the chief executive officer owned 804,919 shares of the company’s stock, valued at approximately $3,783,119.30. This trade represents a 3.87% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Jacob Elguicze purchased 20,000 shares of Embecta stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average price of $4.67 per share, with a total value of $93,400.00. Following the acquisition, the chief financial officer owned 309,139 shares in the company, valued at approximately $1,443,679.13. This represents a 6.92% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 70,000 shares of company stock worth $334,200 over the last three months. 1.30% of the stock is owned by corporate insiders.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.